Last Updated: September 24, 2026

MINOXIDIL EXTRA STRENGTH (FOR MEN) Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Minoxidil Extra Strength (for Men) patents expire, and what generic alternatives are available?

Minoxidil Extra Strength (for Men) is a drug marketed by Apotex Inc, Aurobindo Pharma Ltd, Avacor Prods, P And L, Perrigo, Perrigo New York, and Taro. and is included in seven NDAs.

The generic ingredient in MINOXIDIL EXTRA STRENGTH (FOR MEN) is minoxidil. There is one drug master file entry for this compound. Eighty-six suppliers are listed for this compound. Additional details are available on the minoxidil profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Minoxidil Extra Strength (for Men)

A generic version of MINOXIDIL EXTRA STRENGTH (FOR MEN) was approved as minoxidil by WATSON LABS on March 3rd, 1987.

  Start Trial

AI Deep Research
Ask!
Questions you can ask:
  • What is the 5 year forecast for MINOXIDIL EXTRA STRENGTH (FOR MEN)?
  • What are the global sales for MINOXIDIL EXTRA STRENGTH (FOR MEN)?
  • What is Average Wholesale Price for MINOXIDIL EXTRA STRENGTH (FOR MEN)?
Summary for MINOXIDIL EXTRA STRENGTH (FOR MEN)
US Patents:0
Applicants:7
NDAs:7
Finished Product Suppliers / Packagers: 23
Raw Ingredient (Bulk) Api Vendors: 131
Clinical Trials: 81
DailyMed Link:MINOXIDIL EXTRA STRENGTH (FOR MEN) at DailyMed
Drug patent expirations by year for MINOXIDIL EXTRA STRENGTH (FOR MEN)
Recent Clinical Trials for MINOXIDIL EXTRA STRENGTH (FOR MEN)

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Eurofarma Laboratorios S.A.PHASE3
Sheikh Zayed Federal Postgraduate Medical InstitutePHASE3
Duke UniversityPHASE1

See all MINOXIDIL EXTRA STRENGTH (FOR MEN) clinical trials

Pharmacology for MINOXIDIL EXTRA STRENGTH (FOR MEN)
Drug ClassArteriolar Vasodilator
Physiological EffectArteriolar Vasodilation

US Patents and Regulatory Information for MINOXIDIL EXTRA STRENGTH (FOR MEN)

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Inc MINOXIDIL EXTRA STRENGTH (FOR MEN) minoxidil SOLUTION;TOPICAL 075839-001 Oct 1, 2001 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Taro MINOXIDIL EXTRA STRENGTH (FOR MEN) minoxidil SOLUTION;TOPICAL 217998-001 Jun 30, 2025 OTC No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
P And L MINOXIDIL EXTRA STRENGTH (FOR MEN) minoxidil SOLUTION;TOPICAL 075518-001 Nov 17, 2000 OTC No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Aurobindo Pharma Ltd MINOXIDIL EXTRA STRENGTH (FOR MEN) minoxidil SOLUTION;TOPICAL 075438-001 Feb 27, 2003 OTC No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Avacor Prods MINOXIDIL EXTRA STRENGTH (FOR MEN) minoxidil SOLUTION;TOPICAL 075619-001 Nov 17, 2000 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Perrigo New York MINOXIDIL EXTRA STRENGTH (FOR MEN) minoxidil SOLUTION;TOPICAL 075737-001 Mar 15, 2002 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Perrigo MINOXIDIL EXTRA STRENGTH (FOR MEN) minoxidil SOLUTION;TOPICAL 075598-001 Jun 13, 2001 OTC No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links